Nicole Prutsch
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Multitargeted Reduction of Inflammation and Atherosclerosis in Tet2 -deficient CHIP via XPO1 Inhibition and Atf3 restoration.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Journal: The Journal of clinical investigation
Published: January 04, 2023
Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Journal: British journal of haematology
Published: October 15, 2022
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
Journal: Cell reports. Medicine
Published: September 25, 2022
Retraction Notice to: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Journal: Cell
Published: August 05, 2022
Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Journal: Leukemia
Published: July 16, 2020
Retracted: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Journal: Cell
Published: September 24, 2019
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Journal: Leukemia
Published: September 03, 2019
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Journal: Leukemia
Published: February 25, 2018
Last Updated: 09/26/2026